Farxiga (dapagliflozin) belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It effectively treats Type 2 diabetes by excreting extra sugar in the urine. But medical studies and FDA safety communications link SGLT2 inhibitors to diabetic ketoacidosis, kidney problems and bladder cancer.
If you or a loved one have suffered from ketoacidosis or kidney injury after taking Farxiga, you may be eligible for compensation.
AstraZeneca and Bristol-Myers Squibb’s Farxiga (dapagliflozin) is an oral Type 2 diabetes medication that belongs to a class called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It was the second drug approved in this class. Originally approved in 2014, Farxiga controls blood sugar by preventing the kidneys from reabsorbing sugar and releasing it into the blood. The excess sugar then leaves the body through the urine. Also in 2014, the U.S. Food & Drug Administration approved Xigduo XR, an extended release formula that combines dapagliflozin and metformin.
Each year, more people receive prescriptions for Farxiga. In 2016 alone, AstraZeneca reported $835 million in revenue from the drug. While Farxiga is effective at controlling blood-sugar levels, studies also link it to a number of serious side effects. The FDA released several safety communications warning patients and doctors that Farxiga and other SGLT2 inhibitors may lead to potentially fatal conditions.
While the most common side effect found in studies is female yeast infections, FDA warnings and recent studies link Farxiga to side effects that can be fatal. According to FDA reports, several patients required hospitalization.
Clinical trial data came from 2,338 study participants who took Farxiga 5 mg and 10 mg for an average of 21 weeks. The average age was 55. Half of the participants were male and about 81 percent were white. Participants had Type 2 diabetes for an average of 6 years at the time of the clinical trial.
Since the FDA approved Farxiga in 2014, it released a number of safety communications linking the drug to serious side effects. Studies in clinical trials found a possible increase in the risk of bladder cancer.
In addition, Xigduo XR has a black box warning for lactic acidosis — a known risk of metformin. Lactic acidosis can lead to hypothermia, low blood pressure and death.
During clinical trials, an increased number of patients suffered bladder cancers. As a result, the FDA does not recommend Farxiga for people with active bladder cancer. People with a history of bladder cancer should talk to their doctor. The FDA previously rejected Farxiga’s approval based on bladder and breast-cancer concerns.
In clinical trials, researchers discovered 10 out of 6,045 people who took Farxiga had new cases of bladder cancer, compared to one case in a patient who took a placebo. According to AstraZeneca’s medication insert, “There were too few cases to determine whether the emergence of these events is related to Farxiga.”
Farxiga and Xigduo XR are the only drugs in the SGLT2 class linked to bladder cancer.
In May 2015, the FDA warned that Farxiga and other SGLT2 inhibitors may lead to diabetic ketoacidosis (DKA). DKA is a condition that occurs when the body breaks down fat for energy. The breakdown of fat produces waste products called ketones. Ketones become toxic when they build up in the blood.
In June 2016, the FDA strengthened the acute kidney injury (AKI) warning for Farxiga and Xigduo XR. According to the FDA, more than 100 people reported suffering kidney injuries after taking Farxiga or Invokana between March 2013 and October 2015. These cases are the only ones reported to the FDA Adverse Event Reporting System, and there may be more unreported cases. About 50 percent of the cases occurred within one month of starting the drug.
Weak kidneys can also increase the risk of other Farxiga side effects.
From March 2013 to October 2014, the FDA identified nearly 20 cases of life-threatening blood infections that required hospitalization. In December 2015, the FDA warned that Farxiga can increase the risk of UTIs turning into blood and kidney infections. These conditions can be life threatening.
Farxiga has not been tested adequately in pregnant women. In animal studies, researchers found Farxiga affects kidney development in fetuses. Birth defects in rats occurred at doses 1,441 times the maximum clinical dose. These included malformations of ribs, vertebra, skeletons and blood vessels. Studies also showed Farxiga is excreted in rat milk and juvenile rats exposed to the drug risked problems with kidney development.
“Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney,” according to safety information. Nursing mothers should ask their doctors whether to discontinue use of Farxiga.
Farxiga comes in two strengths: 5 mg and 10 mg. The recommended starting dose is 5 mg taken once daily in the morning with or without food. For patients who need additional glycemic control, doctors may increase the dose to 10 mg.
Patients should get their kidneys tested before starting Farxiga or Xigduo XR. These medications are not recommended in patients with major kidney impairment, according to the medication insert. While taking Farxiga, doctors should continue to monitor kidney function.
Patients should always ask their doctor before taking medications with Farxiga. When taken with insulin and insulin secretagogues, Farxiga can increase the risk of hypoglycemia (low blood sugar). Patients should not use urine glucose tests when taking Farxiga because the increased glucose in urine may lead to a false positive.
Using Xigduo XR with carbonic anhydrase inhibitors (topiramate, zonisamide, acetazolamide or dichlorphenamide), ranolazine, vandetanib, dolutegravir and cimetidine may increase the risk of lactic acidosis.
The medication insert does not recommend taking Xigduo XR with alcohol. It can increase the risk of lactic acidosis.
Scientists evaluated Farxiga’s safety and efficacy in 16 clinical trials with about 9,400 people with Type 2 diabetes. Trials showed an improvement in hemoglobin A1c (HbA1c) — an indication of blood sugar control. But the FDA flagged some outcomes that might pose potential risks to patients and require more data. After the agency approved the drug, it ordered AstraZeneca to conduct post-marketing studies to determine more safety points and efficacy outcomes.
One trial called DECLARE is already underway. This trial will collect data to determine if Farxiga presents an increased risk in cardiovascular or liver problems. This trial will follow more than 17,000 people for four to five years.
Researchers studied Farxiga as a stand-alone therapy and in combination with other drugs to treat Type 2 diabetes. Some of the drugs studied in combination include metformin, Actos (pioglitazone), glimepiride, Januvia (sitagliptin) and insulin.
In a study, 840 patients with inadequately controlled diabetes received Farxiga or a placebo. After 24 weeks, people who took the 10 mg dose achieved the best results. About 50 percent achieved HbA1c levels of less than 7 percent, which is the recommended target point for adults with diabetes. About 44 percent of patients who took a 5 mg dose achieved the same results.
The National Research Center for Women & Families, a patient advocacy nonprofit, called Farxiga “one of the FDAs worst decisions of 2014.” According to the organization’s president, Diana Zuckerman, the drug doesn’t noticeably improve health and comes with serious risks such as breast and bladder cancer.
Then, having discussed Farxiga’s perceived shortcomings and other warnings, Zuckerman wrote in the Huffington Post blog, “But the more frightening news is that patients taking Farxiga in studies done for the FDA were more than five times more likely to contract bladder cancer than the patients who took an older diabetes drug.”
Zuckerman also points out that the majority of participants in clinical trials were white, but African Americans are more likely to have diabetes so there should be more studies on how they are affected.
Please seek the advice of a medical professional before making health care decisions.
Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.
Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.(888) 653-9745